RP-903

N/A

Report date: 2025/10/09 20:00:09
NME

Base Information

Drug NameRP-903
Drug Alias NameRP-903JS-105
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsSolid tumoursPIK3CA-Related Overgrowth SpectrumUterine Cervical Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesRisen(Shanghai) Pharma Tech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJunshi Runjia (Shanghai) Pharmaceutical Technology Co LtdRisen (Suzhou) Pharma Tech Co LtdShanghai Junshi Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPIK3CA-Related Overgrowth SpectrumUterine Cervical Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A